Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Neutralizing antibodies against factor VIII (FVIII) remain the major complication in the replacement therapy of hemophilia A patients. To better understand the evolution of these antibodies it is important to generate comprehensive datasets which include both neutralizing and nonneutralizing